Malmö, Sweden

Tommy Andersson

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 1.2

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Malmo, SE (2014)
  • Malmö, SE (2013 - 2016)

Company Filing History:


Years Active: 2013-2016

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations in Cancer Treatment by Tommy Andersson

Introduction

Tommy Andersson is a notable inventor based in Malmö, Sweden. He has made significant contributions to the field of cancer treatment, particularly focusing on prostate and breast cancer. With a total of 3 patents, his work is paving the way for innovative therapeutic approaches.

Latest Patents

Andersson's latest patents include groundbreaking inventions aimed at improving the prognosis and treatment of prostate cancer. One of his notable inventions involves the use of a Wnt5a protein or peptide, such as Foxy5, for treating prostate cancer, especially in patients who have undergone or will undergo radical prostatectomy. This invention also encompasses a method for determining the prognosis of prostate cancer patients by evaluating the amount of Wnt5a protein in their samples. If the sample value exceeds a reference value, it indicates a better prognosis for the patient.

Another significant patent focuses on a peptide ligand designed to impair cancer cell migration. Research has shown that the loss of Wnt-5a protein expression in breast carcinoma patients correlates with shorter recurrence-free survival. Andersson's work identifies peptide fragments that mimic the effects of Wnt-5a, significantly increasing adhesion and reducing the motility of non-tumorigenic breast cancer cell lines. This research highlights the potential of these peptides as lead substances for anti-metastatic treatments in breast cancers with reduced Wnt-5a expression.

Career Highlights

Tommy Andersson is associated with Wntresearch AB, a company dedicated to advancing cancer research and treatment. His innovative work has garnered attention in the medical community, contributing to the development of new therapeutic strategies for cancer patients.

Collaborations

Andersson collaborates with Anders Bjartell, a fellow researcher in the field. Their combined expertise enhances the potential for breakthroughs in cancer treatment.

Conclusion

Tommy Andersson's contributions to cancer treatment through his innovative patents demonstrate his commitment to improving patient outcomes. His work in utilizing Wnt5a proteins and peptides offers promising avenues for future research and therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…